

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/011303

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/138 A61K31/4196 A61P35/00 A61P43/00
 //(A61K31/138,31:4196)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, MEDLINE, EMBASE, BIOSIS, CANCERLIT

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>GOSS, P.E. ET AL: "A Randomised Trial of Letrozole in Postmenopausal Women after Five Years of Tamixofen Therapy for Early-Stage Breast Cancer"</p> <p>NEW ENGLAND JOURNAL OF MEDICINE, vol. 349, no. 19, 6 November 2003 (2003-11-06), pages 1793-1802, XP002313679</p> <p>This article was published on the web on 9th October 2003.</p> <p>the whole document</p> <p style="text-align: center;">----- -/--</p>	1-20

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the International filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the International filing date but later than the priority date claimed

T later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the International search

18 January 2005

Date of mailing of the international search report

27/01/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Taylor, G.M.

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	GOSS, P.E.: "Breast cancer prevention - clinical trials strategies involving aromatase inhibitors" JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 86, 2003, pages 487-493, XP002313680 This paper was published at the Vith International Aromatase Conference in Kyoto, Japan on 26th-30th October 2002 abstract figure 2 Sections 4 and 7	1-20
X	----- GOSS, P.E.; STRASSER, K.: "Tamoxifen Resistant and Refractory Breast Cancer" DRUGS, vol. 62, no. 2, 2002, pages 957-966, XP009042710 abstract Sections 5 and 6	1-20
X	----- JONES, S.E.: "Antiaromatase Agents: Evolving Role in Adjuvant Therapy" CLINICAL BREAST CANCER, vol. 3, no. 1, 2002, pages 33-42, XP009042715 abstract table 1 page 38 - page 40	1-20
X	----- GOSS, P.E.: "The Evolving Role of Aromatase Inhibitors in the Adjuvant Breast Cancer Setting" AMERICAN JOURNAL OF CANCER, vol. 2, no. 1, January 2003 (2003-01), pages 13-15, XP009042711 the whole document	1-20
X	----- INGLE, J.N. ET AL: "Evaluation of Tamoxifen plus Letrozole with Assessment of Pharmacokinetic Interaction in Postmenopausal Women with Metastatic Breast Cancer" CLINICAL CANCER RESEARCH, vol. 5, 1999, pages 1642-1649, XP002313681 abstract page 1648, col. 1-2, last paragraph	1-20
X	----- GOSS, P.E.: "Preliminary Data from Ongoing Adjuvant Aromatase Inhibitor Trials" CLINICAL CANCER RESEACRH, vol. 7, 2001, pages 4397S-4401S, XP001204817 the whole document ----- -/--	1-20

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	HILL, J; MOORE, H.: "Aromatase inhibitors in breast cancer: Current and evolving roles" CURRENT DRUG THERAPY, vol. 69, no. 7, July 2002 (2002-07), pages 561-567, XP002313886 the whole document	1-20
A	GOSS P: "ANTI-AROMATASE AGENTS IN THE TREATMENT AND PREVENTION OF BREAST CANCER" CANCER CONTROL, H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, TAMPA, US, vol. 9, no. 2, SUPPL, March 2002 (2002-03), pages 2-8, XP001133770 ISSN: 1073-2748 the whole document	1-20
A	GOSS, P.E.; SMITH, R.E.: "Letrozole for the management of breast cancer" EXPERT REVIEW OF ANTICANCER THERAPY, vol. 2, no. 3, 2002, pages 249-260, XP009042714 abstract the whole document	1-20